Sign In
Buy ALNY
$291.22
-6.47 (-2.17%)
At Close: Jun 10, 2026
The Zacks Analyst Blog Highlights ConocoPhillips SAP, CSX, Alnylam Pharmaceuticals and NVR
12:36pm, Thursday, 07'th Jul 2022 Zacks Investment Research
ConocoPhillips, SAP, CSX, Alnylam Pharmaceuticals and NVR are part of Zacks top Analyst Blog.
Top Research Reports for ConocoPhillips, SAP & CSX
08:12pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including ConocoPhillips (COP), SAP SE (SAP), and CSX Corporation (CSX).
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
09:26am, Friday, 01'st Jul 2022 Benzinga
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Only one n
Seven reasons the beleaguered biotech sector is now a 'buy'
11:33am, Saturday, 18'th Jun 2022 MarketWatch
Investors ought to take advantage of low prices for a long-term view.
Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod
03:12pm, Tuesday, 14'th Jun 2022 Zacks Investment Research
The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod
12:24pm, Tuesday, 14'th Jun 2022
The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study
02:51pm, Friday, 10'th Jun 2022 Zacks Investment Research
Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.
Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study
12:02pm, Friday, 10'th Jun 2022
Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022
02:14pm, Tuesday, 07'th Jun 2022 Benzinga
Upgrades
According to Jefferies, the prior rating for Arch Resources Inc (NYSE:ARCH) was changed from Hold to Buy. In the first quarter, Arch Resources showed an EPS of $13.08, compared to $0.40 from
Analyst Ratings for Alnylam Pharmaceuticals
01:01pm, Tuesday, 07'th Jun 2022 Benzinga
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
0
Amgen (AMGN) Olpasiran Lowers Lipoprotein Levels in Phase II
12:47pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
Amgen's (AMGN) olpasiran, a small interfering RNA molecule, is designed in such a way that it lowers the body's production of apolipoprotein(a), a key component of Lp(a) which increases the risk of ca
Time to Weed Your Holdings and Upgrade Your Portfolio
10:49am, Monday, 23'rd May 2022
With the stock market down 18% from its peak as of May 20, now is a good time for a portfolio upgrade.
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
04:34pm, Thursday, 19'th May 2022 Zacks Investment Research
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
02:18pm, Thursday, 19'th May 2022
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View
02:18pm, Friday, 29'th Apr 2022
Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues.
